Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27853199)
Watch
English
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
scientific article
Vemurafenib in Multiple Nonmelanoma Cancers withBRAFV600 Mutations
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
PubMed ID
26287849
retrieved
13 November 2016
title
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
(English)
1 reference
stated in
PubMed
PubMed ID
26287849
retrieved
13 November 2016
author
Igor Puzanov
series ordinal
2
0 references
Jean-Yves Blay
series ordinal
6
object named as
Jean-Yves Blay
0 references
Eli L Diamond
object named as
Eli L Diamond
series ordinal
9
0 references
Josep Tabernero Caturla
object named as
Josep Tabernero
series ordinal
22
0 references
author name string
David M Hyman
series ordinal
1
0 references
Vivek Subbiah
series ordinal
3
0 references
Jason E Faris
series ordinal
4
0 references
Ian Chau
series ordinal
5
0 references
Jürgen Wolf
series ordinal
7
0 references
Noopur S Raje
series ordinal
8
0 references
Antoine Hollebecque
series ordinal
10
0 references
Radj Gervais
series ordinal
11
0 references
Maria Elena Elez-Fernandez
series ordinal
12
0 references
Antoine Italiano
series ordinal
13
0 references
Ralf-Dieter Hofheinz
series ordinal
14
0 references
Manuel Hidalgo
series ordinal
15
0 references
Emily Chan
series ordinal
16
0 references
Martin Schuler
series ordinal
17
0 references
Susan Frances Lasserre
series ordinal
18
0 references
Martina Makrutzki
series ordinal
19
0 references
Florin Sirzen
series ordinal
20
0 references
Maria Luisa Veronese
series ordinal
21
0 references
José Baselga
series ordinal
23
0 references
language of work or name
English
0 references
publication date
20 August 2015
0 references
published in
The New England Journal of Medicine
0 references
volume
373
0 references
page(s)
726-36
0 references
issue
8
0 references
cites work
The Cancer Genome Atlas Pan-Cancer analysis project
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
20 March 2017
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
20 March 2017
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
20 March 2017
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
20 March 2017
BRAF mutations in hairy-cell leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
20 March 2017
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
20 March 2017
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
20 March 2017
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
20 March 2017
Recurrent BRAF mutations in Langerhans cell histiocytosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
20 March 2017
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
20 March 2017
Mutations of the BRAF gene in human cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
20 March 2017
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
20 March 2017
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
20 March 2017
The somatic genomic landscape of glioblastoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
20 March 2017
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
20 March 2017
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
7 April 2017
Distinct sets of genetic alterations in melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
7 April 2017
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
7 April 2017
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
29 September 2017
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
29 September 2017
International uniform response criteria for multiple myeloma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
29 September 2017
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
27 November 2018
BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
27 November 2018
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
27 November 2018
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
27 November 2018
Adaptive two-stage designs for single-arm phase IIA cancer clinical trials.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
27 November 2018
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
27 November 2018
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
27 November 2018
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4971773
retrieved
27 November 2018
BRAFMutation in Metastatic Colorectal Cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/26287849
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1056/NEJMOA1502309
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
1855102
OpenCitations bibliographic resource ID
1855102
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
1855102
PMCID
4971773
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
1855102
PubMed ID
26287849
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
1855102
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
